Oslo, 10 September 2012 - PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the PCI technology with clinical examples will be presented at EACMFS (European Association for Cranio-Maxillo-Facial Surgery) 2012 Congress, Dubrovnik, Croatia (11 - 15 September 2012).
The clinical examples are from the phase I/II study at University College Hospital (UCH) London, UK. The PCI technology and its application in the clinical setting will be presented.
Poster title: Photochemical Internalization (PCI) with Amphinex®: A new technique for local cancer treatment
Presented by Dr Colin Hopper (UCH)
Thursday 13 September 2012, 08:00-12:00 (CET)
Room Elafiti 2, Valamar Lacroma Dubrovnik Hotel,
For more information visit: www.pcibiotech.com
Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Bernt-Olav Røttingsnes, CFO, bor@pcibiotech.no, Mobile: +47 913 47 021
About PCI Biotech
PCI Biotech is a Norwegian biopharmaceutical company developing a novel light directed drug delivery system based on its patented photochemical internalisation (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI method involves first injecting Amphinex® and thereafter the therapeutic drug to be specifically delivered to the diseased cells. When these are illuminated the cells' endosomes are ruptured to allow successful intracellular delivery of the drug.
PCI Biotech focuses on the clinical development of Amphinex® in combination with cancer drugs for localized cancer treatment, based on the company's unique drug delivery platform. Amphinex® is developed in combination with the generic cytotoxic agent bleomycin for head & neck cancer and the generic cytotoxic agent gemcitabine for bile duct cancer.
A preclinical program for the use of PCI to enhance the effect of vaccines is ongoing, with the aim to start a clinical study.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.